Alumis (ALMS) Return on Capital Employed (2024 - 2026)
Alumis (ALMS) posted quarterly Return on Capital Employed of 120.48% for Q4 2025, down 2819.0% year-over-year from 4.43% in Q4 2024, and down 27.9% quarter-over-quarter from 94.2% in Q3 2025.
Alumis (ALMS) Return on Capital Employed (2024 - 2026) Analysis & Trends
Alumis (ALMS) has reported Return on Capital Employed for 2 consecutive years, with 120.48% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Capital Employed fell 2819.0% year-over-year to 120.48%; the TTM figure through Dec 2025 stood at 120.48% (down 2819.0% YoY), while the FY2025 annual figure was 149.7%, up 3325.0% from the prior year.
- Return on Capital Employed slipped to 120.48% in Q4 2025 per ALMS's latest filing, from 94.2% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 79.34% in Q3 2024 and bottomed at 147.36% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.32 Bn | 132.47 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 63.35 Bn | 58.16 Bn | 1.37 Bn | - |
| 4 | Moderna | 63.15 Bn | 58.01 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.96 Bn | 36.86 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 26.09% |
| 7 | Royalty Pharma | 27.67 Bn | 26.83 Bn | - | 7.88% |
| 8 | BioNTech SE | 27.52 Bn | 9.13 Bn | 668.28 Mn | -6.85% |
| 9 | Insmed | 26.98 Bn | 25.82 Bn | 358.27 Mn | -50.93% |
| 10 | Alumis | 3.06 Bn | 2.56 Bn | - | -122.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -122.21% |
| Dec 31, 2025 | -120.48% |
| Sep 30, 2025 | -94.20% |
| Jun 30, 2025 | -125.26% |
| Mar 31, 2025 | -147.36% |
| Dec 31, 2024 | -92.29% |
| Sep 30, 2024 | -79.34% |